Vincerx Pharma Inc
NASDAQ:VINC

Watchlist Manager
Vincerx Pharma Inc Logo
Vincerx Pharma Inc
NASDAQ:VINC
Watchlist
Price: 0.0125 USD
Market Cap: 65.4k USD

Relative Value

There is not enough data to reliably calculate the relative value of VINC.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VINC Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.8
vs History
vs Industry
Median 3Y
-1.7
Median 5Y
-2.5
Industry
24.1
Forward
-0
vs History
vs Industry
Median 3Y
-1.9
Median 5Y
-2.7
Industry
21.8
vs History
vs Industry
Median 3Y
-1.9
Median 5Y
-2.7
Industry
23.8
vs History
93
vs Industry
78
Median 3Y
3.1
Median 5Y
4.4
Industry
3.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.3
vs History
0
vs Industry
26
Median 3Y
-1
Median 5Y
-1.7
Industry
6.3
vs History
0
vs Industry
24
Median 3Y
-1
Median 5Y
-1.7
Industry
6.7
Forward
0.2
vs History
0
vs Industry
28
Median 3Y
-1
Median 5Y
-1.8
Industry
7.9
vs History
0
vs Industry
24
Median 3Y
-1
Median 5Y
-1.8
Industry
6.3
vs History
vs Industry
36
Median 3Y
3.3
Median 5Y
0.7
Industry
5.5

Multiples Across Competitors

VINC Competitors Multiples
Vincerx Pharma Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Vincerx Pharma Inc
NASDAQ:VINC
65.4k USD 0 -0 0.2 0.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 710 712 -160 222 -194 560.6 -192 340.5
US
Abbvie Inc
NYSE:ABBV
407.1B USD 6.8 173.4 16.7 23.7
US
Amgen Inc
NASDAQ:AMGN
179.3B USD 5 25.6 18.4 18.4
US
Gilead Sciences Inc
NASDAQ:GILD
157.2B USD 5.4 19.4 13 13
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.6B USD 9.9 31.7 23.3 24.3
US
Epizyme Inc
F:EPE
94.1B EUR 2 089.8 -533.3 -580.7 -565.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.5B USD 5.8 18 17.2 19.5
AU
CSL Ltd
ASX:CSL
85.1B AUD 3.6 18.9 12.7 15.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
53.5B USD 16.7 1 227.2 161.3 195.6
NL
argenx SE
XBRU:ARGX
44.2B EUR 14.4 33.9 58.5 60.1
P/S Multiple
Revenue Growth P/S to Growth
US
Vincerx Pharma Inc
NASDAQ:VINC
Average P/S: 3 371 286.9
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 710 712
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.8
9%
0.8
US
Amgen Inc
NASDAQ:AMGN
5
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.4
4%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
10%
1
US
E
Epizyme Inc
F:EPE
2 089.8
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.8
6%
1
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.7
46%
0.4
NL
argenx SE
XBRU:ARGX
14.4
49%
0.3
P/E Multiple
Earnings Growth PEG
US
Vincerx Pharma Inc
NASDAQ:VINC
Average P/E: 193.5
Negative Multiple: -0
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 222 N/A N/A
US
Abbvie Inc
NYSE:ABBV
173.4
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.6
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19.4
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.7
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
9%
2
AU
CSL Ltd
ASX:CSL
18.9
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 227.2
N/A N/A
NL
argenx SE
XBRU:ARGX
33.9
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Vincerx Pharma Inc
NASDAQ:VINC
Average EV/EBITDA: 35.7
0.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 560.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.7
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.4
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
13
7%
1.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.3
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -580.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
11%
1.6
AU
CSL Ltd
ASX:CSL
12.7
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
161.3
N/A N/A
NL
argenx SE
XBRU:ARGX
58.5
807%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Vincerx Pharma Inc
NASDAQ:VINC
Average EV/EBIT: 41.2
0.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 340.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.4
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
13
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.3
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.5
13%
1.5
AU
CSL Ltd
ASX:CSL
15.9
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
195.6
N/A N/A
NL
argenx SE
XBRU:ARGX
60.1
N/A N/A